M&A Deal Summary

Compass Therapeutics Acquires TRIGR Therapeutics

On May 13, 2021, Compass Therapeutics acquired life science company TRIGR Therapeutics

Acquisition Highlights
  • This is Compass Therapeutics’ 1st transaction in the Life Science sector.
  • This is Compass Therapeutics’ 1st transaction in the United States.
  • This is Compass Therapeutics’ 1st transaction in California.

M&A Deal Summary

Date 2021-05-13
Target TRIGR Therapeutics
Sector Life Science
Buyer(s) Compass Therapeutics
Deal Type Add-on Acquisition

Target

TRIGR Therapeutics

Irvine, California, United States
TRIGR Therapeutics a private biotechnology oncology company in the field of multi-targeted cancer therapies. TRIGR Therapeutics portfolio of bispecific antibodies includes major mechanisms known to disrupt/halt tumor/ stem cell proliferation (anti-angiogenesis) and activate the immune response (4-1BB engagers) within a single molecule. TRIGR Therapeutics was founded in 2018 and is based in Irvine, California.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Compass Therapeutics

Boston, United Kingdom

Category Company
Founded 2014
Sector Life Science
Employees35
DESCRIPTION

Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain-based multispecific platforms to empirically identify multispecific and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. Compass Therapeutics was incorporated in 2014 and is based in Boston, Massachusetts.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1